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Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disorder of largely
unknown pathogenesis. Recent studies suggest that enhanced oxidative stress
and neuroinflammation contribute to the progression of the disease. Mounting
evidence implicates the receptor for advanced glycation end-products (RAGE) as
a significant contributor to the pathogenesis of certain neurodegenerative diseases
and chronic conditions. It is hypothesized that detrimental actions of RAGE are
triggered upon binding to its ligands, such as AGEs (advanced glycation end products),
S100/calgranulin family members, and High Mobility Group Box-1 (HMGB1) proteins.
Here, we examined the expression of RAGE and its ligands in human ALS spinal cord.
Tissue samples from age-matched human control and ALS spinal cords were tested
for the expression of RAGE, carboxymethyllysine (CML) AGE, S100B, and HMGB1,
and intensity of the immunofluorescent and immunoblotting signals was assessed. We
found that the expression of both RAGE and its ligands was significantly increased in
the spinal cords of ALS patients versus age-matched control subjects. Our study is
the first report describing co-expression of both RAGE and its ligands in human ALS
spinal cords. These findings suggest that further probing of RAGE as a mechanism of
neurodegeneration in human ALS is rational.
Keywords: amyotrophic lateral sclerosis, spinal cord, RAGE, CML, S100B, HMGB1
INTRODUCTION
Amyotrophic lateral sclerosis is a fatal neurodegenerative disorder of upper and lower
motor neurons manifested by progressive muscle wasting, muscular atrophy, and subsequent
respiratory complications, leading to paralysis of respiratory muscles and the diaphragm, with
death usually occurring within 3–5 years after diagnosis (Rowland and Shneider, 2001). The
Abbreviations: AGEs, advanced glycation end products; ALS, Amyotrophic lateral sclerosis; CML, carboxy methyl lysine;
HMGB1, High Mobility Group Box-1; RAGE, receptor for advanced glycation end products.
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pathogenesis of the disease is largely unknown; however, growing
evidence suggests that the progressive neurodegeneration of
motor neurons in ALS results from a combination of multiple
contributing factors, such as oxidative stress, neuroinﬂammation,
glutamate toxicity, mitochondrial dysfunction, neuroﬁlament
disorganization, impaired axonal transport, and excessive
neuronal apoptosis (Mitchell and Borasio, 2007; Brites and Vaz,
2014). Despite extensive eﬀorts, therapies to extend survival and
delay the loss of neuronal function in aﬀected subjects have not
been successful.
The RAGE belongs to the family of the cell surface
immunoglobulins and plays an important role in inﬂammation,
oxidative stress, and cellular dysfunction in a number of
conditions and diseases (Schmidt et al., 2000; Bierhaus et al.,
2004; Daﬀu et al., 2013). Over the last decade, RAGE has
gained attention as a potential contributor to the pathogenesis
of various neurodegenerative diseases and conditions, such as
Alzheimer’s disease (AD), Parkinson’s disease, Huntington’s
disease, Creutzfeldt-Jakob disease, diabetic neuropathy, familial
amyloid polyneuropathy, Charcot neuroarthropathy, and
vasculitic neuropathy (Juranek et al., 2015).
While the speciﬁc molecular mechanisms by which RAGE
contributes to neurodegeneration remain elusive, studies indicate
that the detrimental actions of RAGE are triggered upon
its binding to certain ligands, such as AGEs, members of
the S100/calgranulin family and HMGB1 proteins (Casula
et al., 2011). These ligands are implicated in inﬂammation
and oxidative stress and subsequent activation of downstream
regulatory pathways, such as NF-κB, JNK and STAT1 (Saleh et al.,
2013).
In the central nervous system (CNS), RAGE expression has
been noted in neurons, vascular cells, microglia, and astrocytes,
suggesting its key role in the CNS (Ding and Keller, 2005). The
action of RAGE in these cells depends on the speciﬁc RAGE
isoform and its concentration levels on the cell surface (Ding and
Keller, 2005). It has been observed that in neurons, RAGE-AGE
or RAGE-Amyloid β interaction results in increased oxidative
stress and NF-κB cellular activation (Yan et al., 1996; Mattson
and Camandola, 2001; Mattson, 2004), while in inﬂammatory
cells, RAGE-S100 binding triggers immune cell migration and
synthesis of proinﬂammatory mediators (Hofmann et al., 1999).
On the contrary, studies showed that in neuroblastoma cells,
members of the S100 family triggered RAGE and HMGB1
activation, stimulating axonal outgrowth and improved neuronal
survival (Huttunen et al., 2000; Donato, 2001). In addition,
studies using mouse models of neurodegenerative disease such
as diabetic peripheral neuropathy, AD and Parkinson’s disease
have shown that pharmacological treatment or genetic blockade
of RAGE attenuates diabetes-associated complications, plaque
formation, or MPTP-induced toxicity of dopaminergic neurons,
respectively (Bierhaus et al., 2004; Cho et al., 2009; Teismann
et al., 2012).
Recently, we showed in diabetic mice that genetic deletion
of RAGE improved post injury sciatic nerve regeneration by
reducing tissue inﬂammation at the injury site (Juranek et al.,
2013b). Other studies investigating levels of soluble RAGE
(sRAGE), a natural competitor of RAGE, in ALS and AD showed
a correlation between low levels of plasma sRAGE and the
clinical and pathophysiological manifestation of these diseases
(Emanuele et al., 2005; Ilzecka, 2009; Liang et al., 2013). In
another study, human post-mortem brains of patients aﬀected by
AD and diabetes showed signiﬁcantly increased RAGE and AGE
levels by immunohistochemical staining (Valente et al., 2010).
Here, we examined the expression of RAGE and its ligands
in the spinal cord tissue of human ALS subjects. Our ﬁndings
revealed signiﬁcantly increased expression of RAGE and its three
ligand families in ALS as compared to age-matched controls.
These data suggest that the RAGE axis may contribute to the
pathogenesis of the disease, and that its blockade may be a
rational target for therapeutic intervention in ALS.
MATERIALS AND METHODS
Tissue Collection
For immunohistochemistry experiments, the study utilized de-
identiﬁed age-matched control and ALS surplus thoracic spinal
cord tissue selected from the Columbia University Medical
Center tissue bank from deceased sporadic ALS patients (both
genders; age range 63.6 ± 4.7 years), admitted previously
to the Columbia University Medical Center for diagnosis
and treatment, and from deceased control subjects with no
neurodegenerative disease diagnosis (both genders; age range
50–70 years). The study was approved by the Institutional
Review Board and all study subjects granted their written
informed consent. For mRNA analysis and Western blotting,
de-identiﬁed age-matched control and ALS thoracic spinal
cord tissues were obtained from the University of Pittsburgh
brain tissue bank for neurodegenerative diseases from deceased
sporadic ALS patients and from deceased control subjects with
no neurodegenerative disease diagnosis [all males with age range:
ALS (58.3 ± 5.3 years), controls (62.3 ± 6.9 years); duration of
disease: ALS (32± 8months)]. The brain bank is approved by the
University of Pittsburgh Committee for Oversight of Research
Involving the Dead (CORID). Permission for research was
granted by the next of kin as part of the autopsy authorization.
Immunohistochemistry
Thoracic (T1–T3) spinal cord samples were deparaﬃnized and
subsequently immunostained exactly as we have previously
reported (Juranek et al., 2013a). Brieﬂy, frozen samples were
cut transversely at 10 μm thickness on cryostat (Microm HM
550, Thermo Scientiﬁc, Waltham, MA, USA) and collected
on polylysine coated slides (SuperFrost Plus, Fisher Scientiﬁc,
Pittsburgh, PA, USA), always in the same order – two control
and two ALS sections per each slide set. The investigator
was blinded to the coding of the sections. After collection,
sections were allowed to dry for 2 h at room temperature and
processed according to standard immunostaining protocol. In
brief, dried sections were incubated with blocking solution (Cas-
block, Invitrogen, Carlsbad, CA, USA) for 1 h and incubated
overnight with following primary antibodies: goat anti-RAGE
(1:100; GeneTex, Irvine, CA, USA), mouse anti-S100B (1:100,
Sigma, St. Louis, MO, USA), rabbit anti-HMGB1 (1:100, Abcam,
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Cambridge, MA, USA), and rabbit anti-CML (1:100 Abcam).
The following day, sections were rinsed 4 × 5 min in PBS,
incubated with secondary antibodies: chicken anti-goat Alexa
568, chicken anti-mouse Alexa 488 and chicken anti-rabbit
Alexa 633 (1:300, 1:200, and 1:200, respectively, Invitrogen,
Grand Island, NY, USA) for 1 h, rinsed again 4 × 5 min in
PBS and mounted in Vectashield ﬂuorescent mounting medium
with DAPI (Vector Laboratories, USA). To control speciﬁcity
of secondary antibodies and minimize risk of false positive
results, standard immunostaining procedure with omission or
replacement of primary antibodies on sections from each tissue
sample set was carried out parallel to the experimental staining.
Mounted sections were allowed to stabilize for 30 min and
then examined with Leica SP5 scanning confocal microscope
(Leica SP5, Goettingen, Germany) at 20× objectives (Leica, Plan-
Apochromat air objectives) at one focal plane. Image acquisition
parameters were kept identical for each studied specimen.
Following confocal image acquisition, immunoﬂuorescent signal
quantiﬁcation was carried out using Image J software as
previously described (Juranek et al., 2013a), according to NIH
recommended guidelines and standardized procedures (Prasad
and Prabhu, 2012). Quantitative analysis of the gray matter
thoracic ventral cord lamina IX region immunoﬂuorescent signal
were performed on selected region of interests (ROI, 200 μm2),
three ROIs per each studied control/ALS sample, ﬁve slides per
subject.
RNA Isolation and Quantitative RT-PCR
Total RNA was extracted from spinal cord samples using the
RNeasy mini kit (Qiagen, Valencia, CA, USA). cDNA was
synthesized with iScript cDNA Synthesis Kit (BioRad, Hercules,
CA, USA). Quantitative RT-PCR for AGER was performed using
the TaqMan Fast Universal MasterMix 2Xwith a premade primer
set (Hs00542584_g1; Life Technologies, Carlsbad, CA, USA) for
measurement of the indicated transcripts. The relative abundance
of transcripts was normalized according to the expression of IPO8
house keeping gene.
Western Blot Analysis
Spinal cord tissue samples were homogenized using cell lysis
buﬀer (Cell Signaling, Danvers, MA, USA) and the Bullet
Blender (Next Advance, Averill Park, NY, USA). Total protein
concentrations were quantiﬁed using Quick Start Bradford 1x
Dye (Bio-Rad). Tissue homogenates (30 μg) were subjected
to electrophoresis using 4–12% SDS-PAGE gels and speciﬁc
protein signals were detected using the following antibodies:
mouse anti-β-actin (A1978, 1:4000, Sigma); rabbit anti-RAGE
(GTX23611, 1:1000, GeneTex); rabbit anti-S100B (ab52642,
1:5000, Abcam); and rabbit anti-HMGB1 (GTX101277, 1:1000,
GeneTex). After incubation with indicated antibodies, protein
signals were visualized with IRDye 680RD Goat anti-mouse
(1:25,000; LI-COR, Lincoln, NE, USA) and IRDye 800CW
Goat anti-rabbit (1:10,000; LI-COR) and protein signals were
visualized using the Odyssey Infrared Imaging System Model
9120 (LI-COR). Quantiﬁcation was carried out using Image J
open source software as described previously (Juranek et al.,
2013a).
Statistical Analysis
All values are presented as mean ± standard error (SEM). The
statistical signiﬁcance of diﬀerences (p < 0.05) was evaluated by
non-parametric two-tailed t-test (GraphPad Instat, La Jolla, CA,
USA).
RESULTS
Increased Expression of RAGE and
RAGE Ligands in the ALS Spinal Cord
Here, for the ﬁrst time, we aimed to establish the expression
of RAGE and RAGE ligands in control human spinal
cord and to determine whether and to what extent these
levels were upregulated in ALS tissue. We demonstrate by
immunohistochemistry a signiﬁcantly increased expression of
RAGE in human ALS spinal cord versus control samples. In
the control thoracic spinal cord, overall RAGE expression was
low as compared to ALS samples, (Figures 1A,D, 2A, and 3A).
Quantiﬁcation of RAGE immunoﬂuorescence intensity was
signiﬁcantly higher in ALS tissue versus control (Figure 1B).
By quantitative real-time PCR (RT-PCR), we found a trend
for increased mRNA expression for AGER, the gene encoding
RAGE, in thoracic spinal cords from ALS subjects versus controls
(Figure 1C).
Receptor for advanced glycation end-products ligands showed
increased immunostaining in ALS thoracic spinal cord vs. control
samples (Figures 2B–D and 3B–D, Figure 4C) and analysis
of immunoﬂuorescence intensity was signiﬁcantly higher in
ALS tissue versus control for S100B, HMGB1 and CML, a
prototype AGE protein (Figures 2E–G, respectively). S100B was
sparsely distributed in the control tissue while in ALS thoracic
spinal cord, S100B immunostaining was noticeably increased
(Figures 2B and 3B). HMGB1 immunostaining was also highly
increased in ALS thoracic spinal cord compared to control
tissue (Figures 2C and 3C). CML immunoreactivity was sparsely
distributed in control tissue while in ALS tissue, CML expression
was increased (Figures 2D and 3D). By triple immunostaining,
we show in control tissue, sparse overlapping of RAGE-S100B,
moderate RAGE-CML and RAGE-HMGB1 immunostaining
(Figures 4A,B and 5A,C) whereas in ALS tissue, we found a
high degree of overlapping expression patterns for all ligandswith
RAGE (Figures 4A,B and 5B,D).
Next, we sought to determine relative protein levels of RAGE
and RAGE ligands in thoracic spinal cord samples from ALS
subjects and age-matched controls. Western blotting revealed
that ALS spinal cord tissue had signiﬁcantly higher protein levels
of RAGE, S100B, and HMGB1 compared to control samples
(Figures 6A–C, respectively).
DISCUSSION
In summary, we demonstrate by immunohistochemistry,
quantitative RT-PCR and Western blotting, that ALS spinal
cord tissue displays increased expression of RAGE and RAGE
ligands S100B, CML and HMGB1, suggesting a possible role
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FIGURE 1 | RAGE expression is increased in human ALS spinal cord. (A) Thoracic spinal cord sections were immunostained for RAGE expression from control
(left) or ALS (right) subjects. (B) Quantification of RAGE immunofluorescent staining intensity in spinal cord tissue. Representative images from each group are
shown; control (n = 6) vs. ALS samples (n = 5). (C) mRNA expression levels for AGER were determined by quantitative RT-PCR (n = 3 samples/group).
(D) Magnified images of RAGE immunostaining in ALS and control thoracic spinal cord, motor ventral horn. Clear staining of motor neuron and surrounding area is
visible in the ALS sample as compared to control. Error bars represent mean ± SEM, ∗p < 0.05. Scale bar: 100 μm.
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FIGURE 2 | Expression of RAGE and its ligands in control and ALS thoracic spinal cord tissue. (A) RAGE expression in control (A, top), and in ALS tissue
(A, bottom). (B) S100B immunostaining in control tissue (B, top) and in ALS tissue (B, bottom). (C) HMGB1 immunostaining in the control tissue (C, top) and in ALS
tissue (C, bottom). (D) CML immunostaining in control spinal cord (D, top) and in ALS spinal cord (D, bottom). (E–G) Quantification of immunostaining intensity
revealed that expression of all studied proteins was significantly increased in ALS thoracic spinal cord tissue compared to controls. S100B (E) was increased about
70%, HMGB1 (F) displayed almost threefold increase and CML (G) showed almost double level of increase in immunostaining between ALS and control subjects.
Sections are representative of n = 6 control and n = 5 ALS tissue samples per condition. Error bars represent mean ± SEM, ∗p < 0.05. Scale bar: 50 μm.
for the RAGE pathway in ALS. Until the present time, data
on RAGE expression in ALS patients has been limited to
qualitative rather than quantitative analysis of RAGE expression
in ALS patient spinal cord sections (Casula et al., 2011). Casula
et al. (2011) reported that there was no signiﬁcant change
in AGER mRNA expression in ALS spinal cord, however,
our study revealed a signiﬁcant increase in RAGE expression
in ALS spinal cord by immunohistochemistry, quantitative
RT-PCR and Western blotting. It has been shown that on
average, the correlation between mRNA and protein level is
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FIGURE 3 | High magnification images of immunostaining for RAGE and its ligands in the thoracic spinal cord. Increased immunostaining pattern on the
border of gray (lamina IX) and white matter was observed for (A) RAGE, (B) S100B, (C) HMGB1 and (D) CML in ALS versus control samples. Scale bar: 50 μm.
Frontiers in Cellular Neuroscience | www.frontiersin.org 6 December 2015 | Volume 9 | Article 485
Juranek et al. Increased Expression of RAGE and its Ligands in ALS
FIGURE 4 | Co-expression of RAGE and RAGE ligands S100B, CML, and HMGB1 is higher in human ALS spinal cord. (A) Triple staining for RAGE (red),
S100B (green), CML (blue) revealed increased immunoexpression of these proteins in the ALS spinal cord (A, right) as compared to controls (A, left) and a high
degree of RAGE/ligand overlapping was observed in ALS samples (merged images). (B) Expression of RAGE (red) and its ligands, S100B (green) and HMGB1 (blue)
was highly increased in the ALS (B, right) spinal cord as compared to controls (B, left) and a high degree of RAGE/ligand co-expression observed in ALS samples
(merged images); control (n = 6) vs. ALS samples (n = 5). Scale bar: 100 μm. (C) A schematic diagram showing different regions of spinal cord; for the purpose of
the study we examined thoracic motor spinal cord ventral horn lamina IX and surrounding white matter.
estimated at 40% and since mRNA transcripts are produced
at much lower rates than proteins in mammalian cells (Vogel
and Marcotte, 2012), it is likely that the diﬀerences in mRNA
versus protein levels of RAGE contribute to the observed
discrepancy. A distinct study focused on quantiﬁcation of
circulating soluble endogenous RAGE (sRAGE), a putative
natural antagonist of RAGE in the plasma of control and ALS
patients. This study revealed that sRAGE levels were lower in
the ALS patients and suggested a link between low sRAGE levels
and accelerated neurodegeneration in ALS (Ilzecka, 2009). It is
plausible that the higher expression of RAGE ligands in the ALS
subjects might reduce available sRAGE for immunoreactivity
in ELISA studies. Alternatively, it is possible that subjects with
inherently lower sRAGE levels were more vulnerable to ALS
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FIGURE 5 | High magnification images of white/gray matter showing triple staining for RAGE and its ligands S100B, CML, and HMGB1.
Immunostaining for RAGE (red) and its ligands S100B (green) and CML or HMGB1 (blue) revealed low immunoexpression in control tissue (A and C) and high
immunoexpression in ALS tissue (B and D). Sections are representative of n = 6 control and n = 5 ALS tissue samples per condition. Scale bar: 100 μm.
in the setting of other predisposing factors, such as genetic
vulnerability. Given that sRAGE is a natural scavenger of RAGE
ligands, it is interesting to speculate on the eﬀects of sRAGE
administration as a therapeutic for ALS treatment, as it has been
proposed for metabolic and inﬂammatory diseases (Schmidt,
2015).
Enhanced RAGE expression has been observed in other
neurodegenerative disorders, such as AD (Sasaki et al., 2001;
Wang et al., 2009) and Huntington’s disease (Ma and Nicholson,
2004; Anzilotti et al., 2012), thereby suggesting a potential role
for RAGE in the pathogenesis of these diseases. Indeed, a speciﬁc
polymorphism of theAGER gene (G82S) has been associated with
increased risk of neurodegeneration in two distinct populations
of Chinese and European descent in AD (Daborg et al., 2010; Li
et al., 2010). No studies to date, to our knowledge, have examined
the known polymorphisms of AGER in ALS.
The observed increase in expression of RAGE binding
AGEs, such as CML, reported previously in the spinal cord
of ALS patients (Shibata et al., 1999, 2000; Kikuchi et al.,
2002), further implicates AGE-RAGE contribution to the ALS
pathogenesis, potentially via neuroinﬂammation and oxidative
stress mediation of neuronal damage. Studies show that RAGE
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FIGURE 6 | Protein levels of RAGE and its ligands S100B and HMGB1 are higher in human ALS spinal cord. Western blot analysis of RAGE (A), RAGE
ligands S100B (B) and HMGB1 (C) in control and ALS spinal cord tissue. The original blots were stripped followed by incubation with the other antigens under study.
Signal for test antigen was then normalized to β-actin and the relative band densities were reported. n = 3 subjects/group. Error bars represent mean ± SEM,
∗p < 0.05.
FIGURE 7 | A proposed mechanism of RAGE action in ALS spinal cord.
We propose that during pathological processes in ALS, neuronal and
microglial RAGE becomes activated by RAGE ligands such as AGEs, S100B,
and HMGB1. Once activated, RAGE triggers a cascade of metabolic changes,
contributing to the release of reactive oxygen species (ROS) and inflammatory
cytokines, subsequently resulting in altered protein structures and misfolded
protein accumulation, impaired mitochondrial function and growing energy
deficits ultimately leading to neuronal dysfunction and apoptosis.
may activate macrophage and monocyte inﬂammatory responses
and perpetuate inﬂammation in neurodegenerative diseases,
(Grillo and Colombatto, 2008; Yan et al., 2009; Juranek et al.,
2013b), likely exacerbating neuronal damage in ALS spinal
cord.
HMGB1, another RAGE interacting partner and a member
of the family of damage associated molecular pattern molecules
(Tang et al., 2011), has been implicated in the pathogenesis of
a number of neurodegenerative disorders such as Parkinson’s
disease (Gao et al., 2011), AD (Takata et al., 2004, 2012), multiple
sclerosis and ALS (Lo Coco et al., 2007; Andersson et al., 2008;
Casula et al., 2011; Mazarati et al., 2011) via inﬂammatory toll
like receptor/RAGE signaling pathways activation. It has been
shown that increased expression of HMGB1 correlates with
elevated levels of RAGE and contributes to memory impairment
(Mazarati et al., 2011), demyelination (Andersson et al., 2008),
and neurodegeneration (Gao et al., 2011). The results of our
study show that HMGB1 is signiﬁcantly increased and highly co-
expressed with RAGE in human ALS spinal cord; further studies
will be required to determine if HMGB1 plays important roles in
neurodegenerative processes in the ALS spinal cord.
Similar to HMGB1, elevated levels of astrocyte S100B, another
of RAGE ligands, have been observed in serum of ALS patients
(Sussmuth et al., 2010) and in rat motor neurons exposed to
cerebrospinal ﬂuid from ALS patients (Shobha et al., 2010).
Further, increased cerebrospinal ﬂuid levels of S100B have been
also reported in Parkinson’s disease (Sathe et al., 2012), AD
(Edwards and Robinson, 2006), and schizophrenia (Schmitt
et al., 2005), implying roles for S100B in the pathogenesis of
neurodegenerative diseases. Reports show that RAGE-mediated
inﬂammatory responses trigger S100B activated microglia
stimulation in the brain (Bianchi et al., 2011), leading to neuronal
damage and neurodegeneration and resulting in symptomatic
brain disorders. In addition to potential links to inﬂammation,
studies show that in the cerebellum of spinocerebellar ataxia
type 1 mouse model, S100B-RAGE interaction leads to increased
oxidative stress and further damages neurons contributing to the
progression of the disease (Hearst et al., 2011). Our study reveals
increased expression of S100B in human and mouse ALS spinal
cord indicating that S100B may play an important role in the
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pathogenesis of the disease; it remains to be determined whether
S100B-RAGE interactions in the spinal cord mediate damage via
inﬂammation, oxidative stress or other distinct mechanisms.
Further studies are needed to elucidate the precise molecular
mechanisms of the RAGE/AGE axis in ALS, however our studies
provide a molecular glimpse into these processes. It is reasonable
to speculate that selective loss of motor neurons in ALS occurs
via the RAGE/AGE pathway (Figure 7). Mounting evidence
indicates activated microglia to be a hallmark feature of many
neurodegenerative diseases, including ALS disease progression
(Hall et al., 1998; Henkel et al., 2004; Boillee et al., 2006). RAGE
and its ligands have been implicated in mediating microglia
activation, resulting in chronic inﬂammation and oxidative stress
which upregulates RAGE and ligands such as S100B andHMGB1,
leading to increased oxidative stress and thus creating a positive
feedback loop that most likely results in neuronal cell death (Yan
et al., 1996; Lue et al., 2001; Bianchi et al., 2010, 2007; Fang
et al., 2010). Furthermore, in ALSmicroglial cells, upregulation of
the RAGE/AGE molecules induces formation of reactive oxygen
species (ROS; Frakes et al., 2014) and recently these toxic species
were shown to elicit speciﬁc motor neuron cell death in a non-
cell-autonomous model of ALS via the c-Abl pathway (Rojas
et al., 2015).
Whether RAGE and its ligands are the cause or the modiﬁer
of neurodegenerative disease has yet to be elucidated. However,
the upregulation of these molecules may indicate a mechanism, a
biomarker or both. Our ﬁndings link upregulation of RAGE and
its ligands in ALS aﬀected tissue indicating that these molecules
are worthy of further investigation.
In summary, our study is the ﬁrst to report on diﬀerential,
increased expression of inﬂammatory RAGE and its ligands
in human spinal cord aﬀected by ALS. It must be noted,
however, that our study has been limited to the ﬁnal stage of
the disease due to the timing of availability of spinal cord tissues
consequent to patients’ death and limited sample numbers. No
earlier information on RAGE and its ligand expression could
be obtained for comparative purposes from subjects with ALS
expiring prior to the end stage of the disease. Nevertheless, we
propose that our study provides molecular insights into ALS
pathogenesis and suggests that further probing of the RAGE
hypothesis as a mediator of pathogenesis in human ALS is
rational.
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